Genmab A/S Dkk (GNMSF) 167.0000 $GNMSF Genmab Announces

Genmab A/S Dkk (GNMSF) 167.0000 $GNMSF

Genmab Announces Phase III Studies of Ofatumumab in Relapsing Multiple Sclerosis
GlobeNewswire - Thu Jun 02, 12:50AM CDT
Company Announcement

Genmab Achieves USD 30 Million Milestone in DARZALEX(r) (daratumumab) Collaboration with Janssen
GlobeNewswire - Mon May 30, 10:00AM CDT
Company Announcement

Genmab Announces European Conditional Marketing Authorization for DARZALEX(r) (daratumumab) for Multiple Myeloma
GlobeNewswire - Mon May 23, 6:15AM CDT
Company Announcement

Genmab Announces Positive Topline Result in Phase III POLLUX Study of Daratumumab in Relapsed or Refractory Multiple Myeloma
GlobeNewswire - Wed May 18, 12:29PM CDT
Company Announcement

Ofatumumab in Combination with Fludarabine and Cyclophosphamide for Relapsed CLL accepted for priority review by FDA
GlobeNewswire - Tue May 17, 3:41PM CDT
Company Announcement
GEN: 1.38 (-0.06)

Genmab Announces Financial Results for the First Quarter of 2016
GlobeNewswire - Tue May 10, 10:15AM CDT
Interim Report for the First Quarter of 2016

Genmab Announces Daratumumab Data to be Presented at 2016 ASCO Annual Meeting
GlobeNewswire - Wed Apr 20, 9:53AM CDT
Company Announcement

Patent Infringement Lawsuit Filed Against Genmab and Janssen in the United States Regarding DARZALEX(r)
GlobeNewswire - Mon Apr 04, 1:10PM CDT
Company Announcement

Ad hoc: MorphoSys Sues Janssen Biotech and Genmab for Patent Infringement
GlobeNewswire - Mon Apr 04, 10:48AM CDT
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) today announced that it filed a lawsuit in the United States (U.S.) District Court of Delaware against Janssen Biotech, and Genmab, A/S for patent infringement of U.S. Patent Number 8,263,746. This patent, which is owned by MorphoSys, describes and claims antibodies with particular features that bind to CD38.

CHMP Issues Positive Opinion Recommending DARZALEX(r) (daratumumab) for Relapsed and Refractory Multiple Myeloma
GlobeNewswire - Fri Apr 01, 10:46AM CDT
-- CHMP issued positive opinion for DARZALEX for relapsed and refractory multiple myeloma

First Phase 3 Trial of Daratumumab in Combination with Standard Therapy in Relapsed/Refractory Multiple Myeloma Meets Primary Endpoint in Planned Interim Analysis
PR Newswire - Wed Mar 30, 11:22AM CDT
Janssen Research & Development, LLC announced today positive results of a pre-planned interim analysis of the Phase 3 MMY3004 (CASTOR) trial evaluating the efficacy and safety of daratumumab, a CD38-directed monoclonal antibody (mAb), in combination with bortezomib and dexamethasone, compared to bortezomib and dexamethasone alone, in patients with relapsed or refractory multiple myeloma. The interim analysis, conducted by an Independent Data Monitoring Committee (IDMC), found that the daratumumab combination treatment regimen improved progression-free survival (PFS) compared with bortezomib and dexamethasone alone, achieving the primary study endpoint (p < 0.0001). Based on the recommendation of the IDMC, the study will be stopped early. Study patients originally assigned to the standard treatment group (bortezomib plus dexamethasone) will be offered the option of receiving daratumumab following confirmed disease progression. All patients continue to be followed for long-term safety and overall survival.

Genmab Announces Positive Interim Result in Phase III Castor Study of Daratumumab in Relapsed or Refractory Multiple Myeloma
GlobeNewswire - Wed Mar 30, 11:19AM CDT
Company Announcement

J&J, Roche Tie Up to Study Dual Immunotherapy Combination
Zacks Equity Research - Zacks Investment Research - Wed Mar 23, 3:40PM CDT
Johnson & Johnson (JNJ) inks a clinical trial deal with Roche (RHHBY) to assess dual monoclonal antibody combination therapy.
JNJ: 115.48 (-1.16), AMGN: 149.62 (-2.68)

Genmab Announces Studies of Daratumumab in Combination with Atezolizumab in a Solid Tumor and Multiple Myeloma
GlobeNewswire - Mon Mar 21, 12:23PM CDT
Company Announcement
GEN: 1.38 (-0.06)

Janssen Announces the Initiation of Two Studies Evaluating Daratumumab (DARZALEX®) and Atezolizumab in Multiple Myeloma and Solid Tumor
PR Newswire - Mon Mar 21, 12:17PM CDT
Janssen Research & Development, LLC announced today it has entered into a clinical trial collaboration agreement with Genentech, a member of the Roche Group, to initiate two studies to determine the safety and tolerability of daratumumab (DARZALEX®), the first CD38-directed monoclonal antibody (mAb), in combination with atezolizumab, an investigational mAb designed to bind with a protein called programmed cell death-ligand 1 (PD-L1). These studies will assess the potential of the combination therapy in multiple myeloma and in solid tumor. Atezolizumab is currently in development by Roche. Janssen licensed daratumumab from Genmab A/S and is responsible for development and marketing.

Constitution of the Board of Directors in Genmab A/S and Grant of Warrants to Employees in Genmab
GlobeNewswire - Thu Mar 17, 12:54PM CDT
Following Genmab A/S' (Copenhagen:GEN) Annual General Meeting held on March 17, 2016, the Company's Board of Directors met to constitute itself. Mats Pettersson was appointed Chairman and Dr. Anders Gersel Pedersen was appointed Deputy Chairman. It was decided to issue 24,350 warrants to employees of the Company and one of the Company's subsidiaries.
GEN: 1.38 (-0.06)

Genmab Announces Submission of Supplemental Biologics License Application to FDA for Ofatumumab in Combination with Fludarabine and Cyclophosphamide for Relapsed CLL
GlobeNewswire - Thu Mar 10, 2:01PM CST
Company Announcement

Genmab Achieves Second Milestone in Daratumumab NHL Study Under Collaboration with Janssen
GlobeNewswire - Wed Mar 09, 1:21PM CST
Company Announcement

Genmab Announces European Regulatory Submission for Ofatumumab in Combination with Fludarabine and Cyclophosphamide for Relapsed CLL
GlobeNewswire - Wed Mar 09, 10:04AM CST
Company Announcement
GEN: 1.38 (-0.06)